Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
78.46 USD | -0.09% | +3.55% | +11.42% |
04-17 | ReNeuron Group Reports CFO Resignation | MT |
04-17 | ReNeuron CFO steps down to pursue other opportunities | AN |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The firm trades with high earnings multiples: 21.74 times its 2024 earnings per share.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.42% | 1.64B | B- | ||
-0.24% | 77.64B | B | ||
+2.67% | 47.58B | A- | ||
+3.07% | 32.83B | C | ||
+8.66% | 17.99B | B | ||
-8.29% | 11.81B | B | ||
+12.04% | 11.61B | A- | ||
+1.46% | 10.35B | - | ||
+6.35% | 9.91B | A- | ||
-2.65% | 9.2B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HWKN Stock
- Ratings Hawkins, Inc.